SCHEMBL20657708

SCHEMBL20657708

CCCCCCNC(=O)C(N)Cc1c[nH]c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.60
MMP8 P22894 3/20 0.60
MMP1 P03956 2/20 0.60
TERT O14746 2/20 0.59
ACHE P22303 9/20 0.59
BCHE P06276 8/20 0.59
MMP7 P09237 1/20 0.58
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 1/20 0.58
LMNA P02545 1/20 0.58
MPO P05164 1/20 0.58
MAPT P10636 1/20 0.58
TSHR P16473 1/20 0.58
BLM P54132 1/20 0.58
PMP22 Q01453 1/20 0.58
KMT2A Q03164 1/20 0.58
HIF1A Q16665 1/20 0.58
MTNR1A P48039 1/20 0.57
MMP9 P14780 1/20 0.57
HDAC8 Q9BY41 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17941647 1.00 MMP2 (0.60) MMP2MMP8MMP1TERTACHE
SCHEMBL20281025 1.00 MMP2 (0.60) MMP2MMP8MMP1TERTACHE
SCHEMBL10548878 1.00 MMP2 (0.60) MMP2MMP8MMP1TERTACHE
SCHEMBL20657707 1.00 MMP2 (0.60) MMP2MMP8MMP1TERTACHE
SCHEMBL6573635 1.00 MMP2 (0.60) MMP2MMP8MMP1TERTACHE
SCHEMBL25080947 0.95 KDM4E (0.61) TERTACHEBCHEKDM4EMEN1
SCHEMBL27163831 0.95 KDM4E (0.61) TERTACHEBCHEKDM4EMEN1
SCHEMBL30812923 0.95 KDM4E (0.61) TERTACHEBCHEKDM4EMEN1
Hydrochloric Acid SCHEMBL21082975 0.93 ACHE (0.65) TERTACHEBCHEKDM4EMEN1
Hydrochloric Acid SCHEMBL21082961 0.93 ACHE (0.65) TERTACHEBCHEKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 US disclosed
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 US disclosed
EP-3438091-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-02-06 EP disclosed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 US disclosed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR MMP2 1151/4885MMP8 1439/4885MMP1 2336/4885
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR MMP2 1151/4885MMP8 1439/4885MMP1 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.